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Summary Current anticoagulant provision is dominated by parenteral low-molecular-weight
heparin and oral vitamin K antagonists (VKAs), which indirectly inhibit several steps of the coag-
ulation pathway. Two unmet needs for anticoagulation are safety and ease of use. Safety relates
primarily to the incidence of major bleeding, which remains the key concern of orthopaedic
surgeons and anaesthetists, over and above any efﬁcacy advantage, and convenience of use,
which centres on oral administration replacing the need for injections or monitoring platelets
or coagulation with VKA. Recent research efforts towards identifying small-molecule inhibitors
of coagulation enzymes as novel therapies for thrombotic disorders have been particularly suc-
cessful in developing orally available molecules to directly inhibit the key proteases, factors
IIa and Xa. Of the new oral anticoagulants in development, dabigatran etexilate (BIBR 1048)
and rivaroxaban (BAY 59-7939), which inhibit factors IIa and Xa, respectively, are the most
advanced and were approved in Europe in 2008. Based on the available data, we can conclude
that dabigatran etexilate is non-inferior to enoxaparin in terms of efﬁcacy and safety, and
two different doses (220 and 150mg/day) have now been approved. The 150mg/day dose is
intended for elderly patients and those with moderate renal impairment, which allows clinicians
to decrease the risk of bleeding in the increasing number of fragile patients undergoing major
orthopaedic surgery. In conclusion, rivaroxaban is superior in efﬁcacy to enoxaparin, even with
the US enoxaparin dosing regimen (30mg b.i.d.), without signiﬁcant differences in safety.
© 2009 Elsevier Masson SAS. All rights reserved.
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(40mg/j en Europe et 30mg deux fois par jour aux États-Unis). Enﬁn, cette supériorité existe
aussi pour la première fois sur les événements symptomatiques dans deux études et dans la
méta-analyse sur les quatre études.
© 2009 Elsevier Masson SAS. Tous droits réservés.
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Sbbreviations
LT alanine aminotransferase
I conﬁdence interval
max peak concentration
VT deep vein thrombosis
MEA European Medicines Agency
E pulmonary embolism
D relative difference
RR relative risk reduction
HR total hip replacement
KR total knee replacement
LN upper limit of the normal reference range
TE venous thromboembolism event
ntroduction
urrent anticoagulants for thromboprophylaxis have a
umber of limitations, including parenteral administration
r unpredictable pharmacology that requires monitoring,
nd although they are effective, there remains room for
mprovement. Two unmet needs are safety and ease of use.
afety relates primarily to the incidence of major bleeding,
hich remains the key concern of orthopaedic surgeons and
naesthetists, over and above any efﬁcacy advantage, and
onvenience of use, which centres on oral administration
eplacing the need for injections or monitoring platelets
r coagulation with vitamin K antagonists (VKAs). Despite
he recommendations against using aspirin [1,2], many
atients still receive aspirin to prevent DVT simply because
t is convenient. Therefore, new oral anticoagulants with
A
r
y
kredictable pharmacology may be beneﬁcial. Fondaparinux,
he indirect activated factor X (factor Xa) inhibitor, provides
roof of principle for pure factor Xa inhibition, but has the
isadvantage that it is administered parenterally.
Recent research efforts towards identifying small-
olecule inhibitors of coagulation enzymes as novel
herapies for thrombotic disorders have been particu-
arly successful in developing orally available molecules to
irectly inhibit the key proteases, thrombin (activated fac-
or II; factor IIa) and factor Xa. Several anticoagulants are
urrently in development that target individual coagula-
ion factors. The two agents in the most advanced stage
f development are dabigatran etexilate (BIBR 1048) and
ivaroxaban (BAY 59-7939), which inhibit factor IIa and
actor Xa, respectively. Other agents in the early stages
f development include several Xa inhibitors (LY-517717,
M150, DU-176b and apixaban [BMS-562247]), a factor IXa
nhibitor (TTP889) and an orally active glycosaminoglycan
nhancer (odiparcil [SB-424323]), which indirectly enhances
hrombin inhibition via heparin cofactor II.
This review focuses on the results of trials of dabigatran
texilate and rivaroxaban that support the approval of the
wo drugs in thromboprophylaxis in orthopaedic surgery.
imilarities between phase-III studies328 N. Rosencher et al.
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Résumé Les HBPM, par voie sous-cutanée et les AVK par voie orale inhibent plusieurs facteurs
de la coagulation permettant ainsi d’éviter l’extension d’un thrombus. Les recherches récentes
ont permis de développer des nouvelles molécules synthétiques très spéciﬁques agissant sur un
seul facteur de la coagulation en inhibant directement le IIa ou le Xa. Sur tous les nouveaux
anticoagulants en développement, deux ont déjà l’AMM européenne et sont sur le marché en
Europe : le dabigatran étexilate, commercialisé (Pradaxa®) et le rivaroxaban (Xarelto®) qui
inhibent respectivement le facteur IIa et Xa. Actuellement, les deux principaux apports que
peuvent avoir ces nouvelles molécules sont essentiellement : la commodité d’emploi, apportée
par la voie orale et l’absence de surveillance des plaquettes ou de la coagulation, mais aussi
la tolérance au niveau du saignement, des effets hépatiques et coronariens. Le problème de
tolérance devient primordial pour tous les cliniciens. Dans ce chapitre, ne seront traités que
les deux anticoagulants déjà sur le marché européen : le dabigatran étexilate et le rivarox-
aban. Si on veut résumer le résultat de ces études : pour le dabigatran étexilate, il existe
une non-infériorité en termes d’efﬁcacité et de tolérance en comparaison avec l’énoxaparine.
Cependant, de fac¸on beaucoup plus intéressante, pour la première fois, l’AMM a été accordée
aux deux doses étudiées : 220 et 150mg/j, réservant la dose réduite de 150mg/j aux patients
âgés de plus de 75 ans et insufﬁsants rénaux modérés. Enﬁn, une dose réduite, évaluée efﬁcace
peut être donnée en minimisant le risque de saignement chez cette population particulièrement
fragile. Pour le rivaroxaban, il existe une supériorité en termes d’efﬁcacité en comparaison avec
l’énoxaparine, sans différence signiﬁcative sur la tolérance, en termes de saignements majeurs.
De plus, cette supériorité est retrouvée quel que soit le schéma d’utilisation de l’énoxaparinell trials were prospective, double-blind, double-dummy,
andomized, multicentre studies in adults aged at least 18
ears who were scheduled for primary elective total hip or
nee arthroplasty.
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The primary endpoints for the efﬁcacy analysis were total
VTE (the composite of DVT, non-fatal PE and all-cause mor-
tality) and the composite of major VTE (venographic or
symptomatic proximal DVT and PE) and VTE-related mor-
tality. Bilateral venography was to be performed within 24 h
of the last oral dose. All venograms were assessed centrally
by adjudication committees who were blinded to treatment
allocation and used the same protocol. PE was established by
ventilation—perfusion scintigraphy, pulmonary angiography,
spiral chest computed tomography or autopsy, depending
on local preference. Symptomatic DVT was conﬁrmed by
compression ultrasound or venography and was assessed
centrally by the same VTE-adjudication committee. Deaths
were considered related to VTE if they were categorized
as ‘‘VTE related’’ or ‘‘unexplained’’ by the independent
adjudication committee.
The main safety endpoint was the frequency of major
bleeding events occurring between the ﬁrst dose of study
medication and three days after the last dose. Secondary
safety outcomes included the composite of major and clin-
ically relevant non-major bleeding events, other bleeding
events during treatment, liver enzyme elevation (above
three times and above ﬁve times ULN for serum ALT)
and acute coronary events (deﬁned as conﬁrmed unstable
angina, myocardial infarction and cardiac death). Major,
clinically relevant non-major and minor bleeding events
were classiﬁed by the same independent expert adjudi-
cation committee. All outcomes were assessed by central
independent adjudication committees blinded to treatment
allocation.
Independent committees, blinded to treatment alloca-
tion, reviewed cases of hepatic enzyme abnormalities in
which an ALT above three times ULN had occurred and any
suspected acute coronary syndrome events. An assessment
of causality was provided for each of the patient cases
reviewed.
Concomitant administration of low-dose aspirin
(< 160mg) and selective cyclooxygenase-2 inhibitors was
allowed during treatment. Elastic compression stockings
were permitted and intermittent pneumatic compression
devices were prohibited.
About 25% of patients were excluded from the intention-
to-treat population mainly because bilateral venography
was not performed (usually declined by the patient) or the
venograms were considered indeterminate by the venogra-
phy adjudication committee.
Main differences between the two studies
and the two anticoagulants
There were differences reﬂecting different regulatory
requirements as well as variations in clinical practice
between Europe and North America. According to the conti-
nent, the use of enoxaparin was different: 40mg once daily
starting before surgery or 30mg twice daily starting 12—24 h
postoperatively. In addition, there were differences in the
duration of prophylaxis required following total hip or knee
arthroplasty. In particular, the deﬁnition of major bleeding
was different. In the dabigatran studies, bleeding occur-
ring at the surgical site was considered major in accordance
p
I
i
a329
ith recommended guidelines, while in rivaroxaban stud-
es, the major bleeding deﬁnition did not include surgical
ite bleeding.
Themain differences and similarities between dabigatran
nd rivaroxaban are summarized in Table 1.
abigatran etexilate
abigatran etexilate (Pradaxa®), a novel, oral, reversible,
irect thrombin inhibitor, is being investigated in several
hromboembolic diseases and was approved by the EMEA
n March 2008 for the prevention of VTE in adult patients
ndergoing elective THR or TKR. The onset and offset of
ts anticoagulant activity are rapid and predictable. The
ecommended time for initiating dabigatran etexilate treat-
ent, based on its pharmacokinetic proﬁle, is within 1—4h
ostsurgery with only half a dose on the day of surgery.
bsorption occurs slowly after the ﬁrst postoperative dose
6 h), probably due to alterations in gastric motility after
urgery. In view of the increased bleeding risk immediately
ollowing surgery, this slow and steady absorption proﬁle in
he early postoperative period might represent an advan-
age in that it reduces the risk of postoperative bleeding
3]. Cmax occurs about 6 h after the ﬁrst dose, which means
bout 7—10 h after surgery. In the steady state, absorption
ccurs more rapidly and Cmax occurs about 2 h after admin-
stration.
In all the studies, two different doses of dabigatran
150 and 22mg od) were compared to enoxaparin. The
ncidence of acute coronary syndrome events was similar
etween groups for the duration of the 3-month follow-up
eriod. This observation, together with the lack of any sig-
iﬁcant between-group differences in PE or death during
ollow-up, suggests that there is no rebound effect (i.e.,
o hypercoagulable state after discontinuation of anticoag-
lant treatment) following completion of treatment.
Dabigatran etexilate can be given once daily without
ose adjustments. A linear correlation exists between,
carin clotting time particularly and with prothrombin time,
hrombin clotting time, and plasma dabigatran concentra-
ion, conﬁrming the predictability of the pharmacokinetics
nd pharmacodynamics of dabigatran. With the exception
f individuals with signiﬁcant renal impairment (creatinine
learance 30—50mL/min), dose reduction is not needed in
nique populations, such as obese patients or those from
ifferent ethnic backgrounds.
Dabigatran etexilate was as effective as enoxaparin for
he primary prevention of VTE, with a similar safety proﬁle,
n the two phase III trials (RE-MODELTM [4] and RE-NOVATETM
5]) that led to approval in the European Union (Table 2).
he primary efﬁcacy endpoint (total VTE) was not reached in
E-MOBILZE [6] because of the comparison between enoxa-
arin 30mg twice daily with the same dose of dabigatran
tarted later (6—8days). However, there was no signiﬁcant
ifference in major VTE and there was a trend to less major
leeding (0.6%) in the dabigatran group than in the enoxa-
arin group (1.4%).
A pooled analysis of major VTE was presented at the
nternational Society on Thrombosis and Haemostasis meet-
ng in 2007 [7]. The composite of major VTE (proximal DVT
nd/or PE) and VTE-related mortality occurred in 3.3% (69
330 N. Rosencher et al.
Table 1 Drug characteristics.
Dabigatran etexilate (anti-IIa) Rivaroxaban (anti-Xa)
Approved by EMEA March 2008 September 2008
Indications Prevention of VTE in adults undergoing THR or
TKR
Prevention of VTE in adults undergoing THR or
TKR
Doses 150mg/day if > 75 years otherwise 220mg/day 10mg/day
Administration Oral o.d.
Half dose the 1st day, started 4—6h after the
end of surgery
Oral o.d.
Full dose 1st day, started 6—10 h after the end
of surgery
Contraindications Quinidine use
Pregnancy, lactation
Severe renal insufﬁciency
Hepatic disease associated with coagulopathy
Pregnancy, lactation
Azole antimycotics
HIV protease inhibitors
Severe renal insufﬁciency
Hepatic disease associated with coagulopathy
Bioavailability (%) 6.5 80—100
Binding protein (%) 34—35 92—95
Tmax (h) 2—4
6 the 1st day
2—4
Half-life (h) 14—17 7—11
Elimination Urinary (85%)
Faecal (6%)
Urinary (65%), but only 33% in active
metabolites
Faecal (35%)
Careful use > 75 years
Moderate renal impairment (CLCR
30—50mL/min)
< 50 kg or > 110 kg
Amiodarone
Cirrhotic with moderate hepatic impairment
(Child Pugh B) without coagulopathy
Interaction Quinidine Azole-antimytotics
HIV protease inhibitors
Monitoring No No
Antidote Not available (dialysable) Not available (not dialysable)
CLCR: creatinine clearance; EMEA: European Medicines Agency; o.d.: once daily; THR: total hip replacement; TKR: total knee
replacement; Tmax: time to peak concentration; VTE: venous thromboembolism.
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af 2096) of the enoxaparin group, 3.0% (62 of 2033) of the
abigatran etexilate 220mg group (RD −0.2%, 95% CI —1.3 to
.9%, I2 = 37%) and 3.8% (78 of 2071) of the 150mg group (RD
.5%, 95% CI —0.6 to 1.6%, I2 = 0%). Major bleeding occurred
n 1.4% of the enoxaparin group, 1.4% of the dabigatran etex-
late 220mg group (RD −0.2%, 95% CI −0.8 to 0.5%, I2 = 40%)
nd 1.1% of the 150mg group (RD —0.4%, 95% CI −1.0 to
.2%, I2 = 0%). Most of the major bleeding events (80—90%)
ccurred at the surgical site. In the European trials, where
he design was similar in terms of time of the ﬁrst dose of
noxaparin and dabigatran etexilate, about half of themajor
leeding events in the dabigatran groups (44% in the 220mg
roup, 50% in the 150mg group) occurred before any active
rug was given.
The EMEA has decided that the 150mg dose should be
sed in patients aged over 75 years or in individuals with
oderate renal impairment (and if concomitantly treated
ith amiodarone) and the 220mg dose for all other patients.
i
h
F
i
lccording to the latest American College of Chest Physicians
uidelines [1], the low-molecular-weight heparin (LMWH)
ose should be reduced in elderly patients or those with
enal impairment, but without recommendation about the
ose needed because no study currently shows that a lower
ose of LMWH is efﬁcacious in this population. With dabi-
atran, the 150mg dose was studied in many patients and
he efﬁcacy was demonstrated with a trend to less major
leeding in this population [8]. The question now is how
mportant is adherence to oral treatment? The half-life is
7 h in elderly patients, thus if the patients forgets or skips
dose 1 day after discharge, they are not at high risk of
thromboembolic event. Indeed, the risk is very high dur-ng the ﬁrst 7 days (during which the patient is generally
ospitalized) and decreases thereafter, especially in TKR.
urthermore, this population is used to taking several med-
cations, and they often use a pillbox, which reduces the
ikelihood of missed doses.
New oral anticoagulants for orthopaedic thromboprophylaxis
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ivaroxaban
ivaroxaban (Xarelto®) is a novel, oral, direct factor Xa
nhibitor. Phase II studies demonstrated that rivaroxaban
as potentially safe and effective for thromboprophylaxis
fter major orthopaedic surgery across a wide dose range.
ivaroxaban total daily doses of 5—20mg had similar efﬁcacy
o enoxaparin after THR and TKR, which probably means a
ery large therapeutic window. Several phase III studies with
ivaroxaban 10mg once daily have been published. RECORD
, 2 and 3 compared rivaroxaban with enoxaparin 40mg
nce daily. RECORD 1 and 2 compared extended rivaroxa-
an treatment to short-duration enoxaparin treatment in
atients undergoing THR. RECORD 3 and 4 compared rivarox-
ban to enoxaparin in patients undergoing TKR; RECORD 4
sed the US-approved enoxaparin regimen. Details of these
rials are described in Table 3.
HR: RECORD 1 and 2
verall, RECORD 1 showed superiority for rivaroxaban,
emonstrating a 70% RRR (p < 0.001) in total VTE compared
ith enoxaparin, and an 88% RRR (p < 0.001) in major VTE
9]. The superior efﬁcacy of rivaroxaban was not associated
ith any signiﬁcant differences in the incidence of major
leeding between the rivaroxaban and enoxaparin groups
0.3 and 0.1%, respectively, p = 0.178). Rivaroxaban was not
ssociated with compromised liver function.
Overall, RECORD 2 demonstrated a 79% RRR in total VTE
or extended rivaroxaban treatment (p < 0.0001) and an 88%
RR (p < 0.0001) in major VTE [10]. The superior efﬁcacy
f rivaroxaban was not associated with any signiﬁcant dif-
erences in the incidence of major bleeding between groups
< 0.1% in both groups). Rivaroxaban was not associated with
ompromised liver function.
The main difference between RECORD 1 and 2 was the
uration of prophylaxis in the enoxaparin arm. Indeed, in
ECORD 2, enoxaparin was given for only 2 weeks, while
ivaroxaban was given for 4 weeks. The results of both stud-
es have shown superiority for rivaroxaban, as expected, but
lso signiﬁcant superiority in preventing symptomatic DVT.
ore interestingly, there was no difference in major bleed-
ng, even when enoxaparin was stopped after 2 weeks, which
eans that, the rate of major bleeding occur in the ﬁrst days
fter surgery and rarely after discharge.
KR: RECORD 3 and 4
verall, RECORD 3 demonstrated a 49% RRR (p < 0.001) in
otal VTE for rivaroxaban compared with enoxaparin, and
62% RRR (p < 0.016) in major VTE [11]. Most interestingly,
here was a signiﬁcantly lower rate of symptomatic DVT in
he rivaroxaban group than in the enoxaparin group. The
uperior efﬁcacy of rivaroxaban was not associated with any
igniﬁcant differences in the incidence of major bleeding
etween the rivaroxaban and enoxaparin groups (0.6 and
.5% respectively, p = 0.774). Rivaroxaban was not associ-
ted with compromised liver function.
In RECORD 4, rivaroxaban 10mg once daily was compared
o the US-approved enoxaparin regimen of 30mg injected
wice daily. There was a 31% RRR in total VTE with rivaroxa-
an compared with enoxaparin, with a similar safety proﬁle.
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RN. Rosencher et al.
oth treatments were continued for 10—14 days. Top-line
esults from this study were ﬁrst presented in May 2008 at
he annual meeting of the European Federation of National
ssociations of Orthopaedics and Traumatology.
The results of a prespeciﬁed pooled analysis to evaluate
he effect of rivaroxaban on the composite of symptomatic
TE and death, as well as bleeding, was presented by Turpie
t al. at the American Society of Haematology meeting
12]. These primary outcomes were analysed at day 12± 2
n the active treatment pool (i.e., during the enoxaparin-
ontrolled period common to all studies, to allow for
nbiased comparison with enoxaparin) and for the total
tudy duration pool (planned treatment period and 30—35
ays of follow-up). Rivaroxaban reduced the incidence of
ymptomatic VTE and all cause of mortality signiﬁcantly
ompared with enoxaparin at day 12± 2 (0.47% vs 0.97%,
= 0.001) and for the total study duration (0.81% vs 1.63%,
< 0.001). Rivaroxaban was not associated with a statis-
ically signiﬁcant increased risk of major bleeding. Most
nterestingly, the combined criteria of death, symptomatic
TE, myocardial infarction, stroke and major bleeding, was
igniﬁcantly lower in the rivaroxaban group compared with
he enoxaparin group (p = 0.004).
onclusions
hese new oral anticoagulants feature some major
dvantages over traditional anticoagulants, including no
equirement for anticoagulant monitoring, a low drug—drug
nteraction potential and the possibility to use in both the
cute and chronic settings. These drugs provide an alter-
ative to subcutaneous enoxaparin for the prevention of
TE after THR and TKR. Rivaroxaban demonstrated superior
fﬁcacy over enoxaparin even in symptomatic DVT, without
igniﬁcant differences in major bleeding. Dabigatran etex-
late is the ﬁrst anticoagulant registered and approved by
he EMEA with two different doses and, for the ﬁrst time,
ne reduced dose is deﬁned for the elderly population or for
atients with moderate renal insufﬁciency.
A report from the UK National Health Service indi-
ates that only about half of patients undergoing major
rthopaedic surgery who are at high risk of thromboem-
olic complications receive effective thromboprophylaxis.
lthough aspirin is not recommended [1], it is overused in
any countries because its oral form makes it convenient.
he approval of dabigatran etexilate and rivaroxaban has
he potential to greatly improve this situation, as they have
everal advantages over current treatments: they are oral
rugs that can be easily administered in hospital and after
ischarge, and offer the prospect of a longer duration of
rophylaxis with higher adherence. The main interest will
robably be to improve the prescription and the adherence
o an effective thromboprophylaxis regimen for medical
ssues such as atrial ﬁbrillation without the bleeding side-
ffects seen with LMWH or the coagulation monitoring
equired with VKA treatment.eferences
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